The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...